Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track VTRS with free AI briefings, catalyst countdowns, and dilution alerts.

VTRS · Viatris Inc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.8B Cash on Hand
CF+ Cash Runway
Follow VTRS by email Get an email when VTRS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VTRS, unsubscribe in one click. Privacy

📣 What VTRS Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tyrvaya Dry Eye N/A · NCT07705893 Recruiting
Treatment with 137 µg azelastine hydrochloride… Allergic Rhinitis Due to Allergens Phase 4 · NCT07597473 Completed
Revefenacin COPD Exacerbation Phase 4 · NCT07721922 Not yet recruiting
Oxycodone Healthy Phase 4 · NCT07813026 Recruiting
Tramadol Acute Pain Phase 3 · NCT06215859 Completed
Deoxycholate Amphotericin B (DAmB) Talaromycosis Phase 3 · NCT06525389 Not yet recruiting
Pimecrolimus 0.3% Ophthalmic Ointment Blepharitis Phase 3 · NCT06400511 Terminated
phentolamine ophthalmic solution 0.75%, a… Mesopic Vision Phase 3 · NCT06349759 Completed
MR-107A-02 Acute Pain Phase 3 · NCT06215859 Completed
Liposomal Amphotericin B Talaromycosis Phase 3 · NCT06525389 Not yet recruiting
Cenerimod Nephritis, Lupus Phase 3 · NCT07201129 Recruiting
Bedaquiline MDR-TB Phase 3 · NCT07486024 Recruiting
Selatogrel Acute Myocardial Infarction Phase 2 · NCT03487445 Completed
AC-076 for s.c. administration Healthy Subjects Phase 1 · NCT03173625 Completed
ACT-334441 2 mg Healthy Subjects Phase 1 · NCT02479204 Terminated
Ethinyl Estradiol Healthy Subjects Phase 1 · NCT04255277 Completed

Also used in these trials (approved or third-party drugs, not VTRS's own candidates): Gabapentin, Varenicline, Sildenafil, Ipratropium Bromide, Formoterol Fumarate, Albuterol Sulfate, Alprazolam, Flucytosine, Rifampicin, Ticagrelor, Clopidogrel Bisulfate, Atenolol.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VTRS holds $1.8B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VTRS files for a raise →

👥 Who Owns VTRS

Insiders 0.3% Institutions (1391 holders) 95.4% Public and other holders 4.3%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 126,764,446 11.06% 2026-08-31
Vanguard Capital Management Institution (13G, 5%+) 84,807,083 7.40% 2026-03-31
DAVIS SELECTED ADVISERS Institution (13G, 5%+) 72,403,329 6.32% 2026-09-30
Scott Andrew Smith
Chief Executive Officer, Director · +1.56M options
Insider 1,329,326 0.12% 2026-03-06
Paul Campbell
Officer · +229,185 options
Insider 316,530 0.03% 2026-06-25
Andrew Enrietti
Chief Administrative and Transformation · +162,894 options
Insider 234,444 0.02% 2026-08-15
Melina E Higgins
Director · +15,890 options
Insider 220,048 0.02% 2026-03-06
Mark W Parrish
Director · +15,890 options
Insider 165,230 0.01% 2026-03-06
James M Kilts
Director · +15,890 options
Insider 161,257 0.01% 2026-03-06
Richard A Mark
Director · +15,890 options
Insider 116,145 0.01% 2026-03-06
W Don Cornwell
Director · +15,890 options
Insider 112,044 0.01% 2026-03-06
Goff Corinne Le
Chief Commercial Officer
Insider 107,135 0.01% 2026-04-15

Share count 1,146,454,729 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full VTRS picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VTRS and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.